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Abstract
The Concise Guide to PHARMACOLOGY 2017/18 provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available),
plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise
Guide represents approximately 400 pages, the material presented is substantially reduced compared to information and links presented on the website. It provides a permanent, citable, point-in-time
record that will survive database updates. The full contents of this section can be found at http://onlinelibrary.wiley.com/doi/10.1111/bph.13880/full. Nuclear hormone receptors are one of the eight
major pharmacological targets into which the Guide is divided, with the others being: G protein-coupled receptors, ligand-gated ion channels, voltage-gated ion channels, other ion channels, catalytic
receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for
further reading. The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to mid-2017, and supersedes data presented in the 2015/16
and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in close conjunction with the Nomenclature Committee of the Union of Basic and Clinical Pharmacology
(NC-IUPHAR), therefore, providing ofﬁcial IUPHAR classiﬁcation and nomenclature for human drug targets, where appropriate.
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Overview: Nuclear receptors are specialised transcription fac-
tors with commonalities of sequence and structure, which bind
as homo- or heterodimers to speciﬁc consensus sequences of DNA
(response elements) in the promoter region of particular target
genes. They regulate (either promoting or repressing) transcrip-
tion of these target genes in response to a variety of endogenous
ligands. Endogenous agonists are hydrophobic entities which,
when bound to the receptor promote conformational changes
in the receptor to allow recruitment (or dissociation) of protein
partners, generating a large multiprotein complex.
Twomajor subclasses of nuclear receptors with identiﬁed endoge-
nous agonists can be identiﬁed: steroid and non-steroid hor-
mone receptors. Steroid hormone receptors function typically
as dimeric entities and are thought to be resident outside the
nucleus in the unliganded state in a complex with chaperone
proteins, which are liberated upon agonist binding. Migration
to the nucleus and interaction with other regulators of gene
transcription, including RNA polymerase, acetyltransferases and
deacetylases, allows gene transcription to be regulated. Non-
steroid hormone receptors typically exhibit a greater distribution
in the nucleus in the unliganded state and interact with other
nuclear receptors to form heterodimers, as well as with other reg-
ulators of gene transcription, leading to changes in gene tran-
scription upon agonist binding.
Selectivity of gene regulation is brought about through interac-
tion of nuclear receptors with particular consensus sequences of
DNA, which are arranged typically as repeats or inverted palin-
dromes to allow accumulation of multiple transcription factors
in the promoter regions of genes.
Searchable database: http://www.guidetopharmacology.org/index.jsp Nuclear hormone receptors S208
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Family structure
S209 1A. Thyroid hormone receptors
S210 1B. Retinoic acid receptors
S210 1C. Peroxisome proliferator-activated receptors
S211 1D. Rev-Erb receptors
S212 1F. Retinoic acid-related orphans
S212 1H. Liver X receptor-like receptors
S213 1I. Vitamin D receptor-like receptors
S214 2A. Hepatocyte nuclear factor-4 receptors
S215 2B. Retinoid X receptors
S216 2C. Testicular receptors
S216 2E. Tailless-like receptors
S217 2F. COUP-TF-like receptors
S217 3B. Estrogen-related receptors
S218 4A. Nerve growth factor IB-like receptors
S219 5A. Fushi tarazu F1-like receptors
S219 6A. Germ cell nuclear factor receptors
S220 0B. DAX-like receptors
S221 Steroid hormone receptors
S221 3A. Estrogen receptors
S222 3C. 3-Ketosteroid receptors
1A. Thyroid hormone receptors
Nuclear hormone receptors→ 1A. Thyroid hormone receptors
Overview: Thyroid hormone receptors (TRs, nomencla-
ture as agreed by the NC-IUPHAR Subcommittee on
Nuclear Hormone Receptors [41]) are nuclear hormone
receptors of the NR1A family, with diverse roles regulating
macronutrient metabolism, cognition and cardiovascular home-
ostasis. TRs are activated by thyroxine (T4) and thyroid hormone
(triiodothyronine). Once activated by a ligand, the receptor acts
as a transcription factor either as a monomer, homodimer or het-
erodimer with members of the retinoid X receptor family. NH-3
has been described as an antagonist at TRs withmodest selectivity
for TRβ [110].
Nomenclature Thyroid hormone receptor-α Thyroid hormone receptor-β
Systematic nomenclature NR1A1 NR1A2
HGNC, UniProt THRA, P10827 THRB, P10828
Rank order of potency triiodothyronine > T4 triiodothyronine > T4
Agonists dextrothyroxine [19] dextrothyroxine [19]
Selective agonists – sobetirome [26, 130]
Comments: An interaction with integrin αVβ3 has been suggested to underlie plasma membrane localization of TRs and non-genomic signalling [8].One splice variant, TRα2, lacks a functional DNA-
binding domain and appears to act as a transcription suppressor.
Although radioligand binding assays have been described for these receptors, the radioligands are not commercially available.
Further reading on 1A. Thyroid hormone receptors
Davis PJ et al. (2016) Nongenomic actions of thyroid hormone. Nat Rev Endocrinol 12: 111-21
[PMID:26668118]
Elbers LP et al. (2016) Thyroid Hormone Mimetics: the Past, Current Status and Future Challenges.
Curr Atheroscler Rep 18: 14 [PMID:26886134]
Flamant F et al. (2006) International Union of Pharmacology. LIX. The pharmacology and classi-
ﬁcation of the nuclear receptor superfamily: thyroid hormone receptors. Pharmacol. Rev. 58:
705-11 [PMID:17132849]
Mendoza A et al. (2017) New insights into thyroid hormone action. Pharmacol Ther 173: 135-145
[PMID:28174093]
Searchable database: http://www.guidetopharmacology.org/index.jsp 1A. Thyroid hormone receptors S209
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1B. Retinoic acid receptors
Nuclear hormone receptors→ 1B. Retinoic acid receptors
Overview: Retinoic acid receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Nuclear Hormone Receptors [46]) are nuclear hormone receptors of the NR1B family
activated by the vitamin A-derived agonists tretinoin (ATRA) and alitretinoin, and the RAR-selective synthetic agonists TTNPB and adapalene. BMS493 is a family-selective antagonist [47].
Nomenclature Retinoic acid receptor-α Retinoic acid receptor-β Retinoic acid receptor-γ
Systematic nomenclature NR1B1 NR1B2 NR1B3
HGNC, UniProt RARA, P10276 RARB, P10826 RARG, P13631
Agonists tretinoin [25] tretinoin [25] tretinoin [25]
Sub/family-selective agonists tazarotene [25] tazarotene [25], adapalene [24] tazarotene [25], adapalene [24]
Selective agonists BMS753 [53], tamibarotene [146], Ro 40-6055 [33] AC261066 [89], AC55649 [88, 89] AHPN [24]
Selective antagonists Ro 41-5253 (pIC50 6.3–7.2) [2, 69] – MM 11253 [76]
Comments: Ro 41-5253 has been suggested to be a PPARγ agonist [129]. LE135 is an antagonist with selectivity for RARα and RARβ compared with RARγ [84].
Further reading on 1B. Retinoic acid receptors
Duong V et al. (2011) The molecular physiology of nuclear retinoic acid receptors. From health to
disease. Biochim. Biophys. Acta 1812: 1023-31 [PMID:20970498]
Germain P et al. (2006) International Union of Pharmacology. LX. Retinoic acid receptors. Phar-
macol. Rev. 58: 712-25 [PMID:17132850]
Larange A et al. (2016) Retinoic Acid and Retinoic Acid Receptors as Pleiotropic Modulators of the
Immune System. Annu Rev Immunol 34: 369-94 [PMID:27168242]
Saeed A et al. (2017) The interrelationship between bile acid and vitamin A homeostasis. Biochim
Biophys Acta 1862: 496-512 [PMID:28111285]
1C. Peroxisome proliferator-activated receptors
Nuclear hormone receptors→ 1C. Peroxisome proliferator-activated receptors
Overview: Peroxisome proliferator-activated receptors (PPARs,
nomenclature as agreed by the NC-IUPHAR Subcom-
mittee on Nuclear Hormone Receptors [101]) are nuclear
hormone receptors of the NR1C family, with diverse roles reg-
ulating lipid homeostasis, cellular differentiation, proliferation
and the immune response. PPARs have many potential endoge-
nous agonists [13, 101], including 15-deoxy-12,14-PGJ2, prosta-
cyclin (PGI2), many fatty acids and their oxidation products,
lysophosphatidic acid (LPA) [98], 13-HODE, 15S-HETE, Paz-PC,
azelaoyl-PAF and leukotriene B4 (LTB4). Bezaﬁbrate acts as a
non-selective agonist for the PPAR family [155]. These recep-
tors also bind hypolipidaemic drugs (PPARα) and anti-diabetic
thiazolidinediones (PPARγ), as well as many non-steroidal anti-
inﬂammatory drugs, such as sulindac and indomethacin. Once
activated by a ligand, the receptor forms a heterodimer with
members of the retinoid X receptor family and can act as a tran-
scription factor. Although radioligand binding assays have been
described for all three receptors, the radioligands are not com-
mercially available. Commonly, receptor occupancy studies are
conducted using ﬂuorescent ligands and truncated forms of the
receptor limited to the ligand binding domain.
Searchable database: http://www.guidetopharmacology.org/index.jsp 1C. Peroxisome proliferator-activated receptors S210
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Nomenclature Peroxisome proliferator-activated receptor-α Peroxisome proliferator-activated receptor-β/δ Peroxisome proliferator-activated receptor-γ
Systematic
nomenclature
NR1C1 NR1C2 NR1C3
HGNC, UniProt PPARA, Q07869 PPARD, Q03181 PPARG, P37231
Selective
agonists
GW7647 [17, 18], CP-775146 [67],
pirinixic acid [155], gemﬁbrozil [31]
GW0742X [50, 148], GW501516 [112] GW1929 [17], bardoxolone (Partial agonist) [149],
rosiglitazone [59, 80, 86, 161], troglitazone [59, 161],
pioglitazone [7, 59, 127, 161], ciglitazone [59]
Selective
antagonists
GW6471 (pIC50 6.6) [158] GSK0660 (pIC50 6.5) [131] T0070907 (pKi 9) [77], GW9662 (Irreversible inhibition)
(pIC50 8.1) [78], CDDO-Me (pKi 6.9) [149]
Comments: As with the estrogen receptor antagonists, many agents show tissue-selective efﬁcacy (e.g. [12, 109, 124]). Agonists with mixed activity at PPARα and PPARγ have also been described (e.g [35,
52, 159]).
Further reading on 1C. Peroxisome proliferator-activated receptors
CheangWS et al. (2015) The peroxisome proliferator-activated receptors in cardiovascular diseases:
experimental beneﬁts and clinical challenges. Br J Pharmacol 172: 5512-22 [PMID:25438608]
Gross B et al. (2017) PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD.Nat Rev Endocrinol
13: 36-49 [PMID:27636730]
Hallenborg P et al. (2016) The elusive endogenous adipogenic PPARgamma agonists: Lining up the
suspects. Prog Lipid Res 61: 149-62 [PMID:26703188]
Michalik L et al. (2006) International Union of Pharmacology. LXI. Peroxisome proliferator-
activated receptors. Pharmacol. Rev. 58: 726-41 [PMID:17132851]
Sauer S. (2015) Ligands for the Nuclear Peroxisome Proliferator-Activated Receptor Gamma. Trends
Pharmacol Sci 36: 688-704 [PMID:26435213]
1D. Rev-Erb receptors
Nuclear hormone receptors→ 1D. Rev-Erb receptors
Overview: Rev-erb receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Nuclear Hormone Receptors [6]) have yet to be ofﬁcially paired with an endogenous ligand,
but are thought to be activated by heme.
Nomenclature Rev-Erb-α Rev-Erb-β
Systematic nomenclature NR1D1 NR1D2
HGNC, UniProt NR1D1, P20393 NR1D2, Q14995
Endogenous agonists heme [121, 160] heme [97, 121, 160]
Selective agonists GSK4112 [51], GSK4112 [70] –
Selective antagonists SR8278 (pIC50 6.5) [70] –
Searchable database: http://www.guidetopharmacology.org/index.jsp 1D. Rev-Erb receptors S211
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Further reading on 1D. Rev-Erb receptors
Benoit G et al. (2006) International Union of Pharmacology. LXVI. Orphan nuclear receptors.
Pharmacol. Rev. 58: 798-836 [PMID:17132856]
Gonzalez-Sanchez E et al. (2015) Nuclear receptors in acute and chronic cholestasis. Dig Dis 33:
357-66 [PMID:26045270]
Gustafson CL et al. (2015) Emerging models for the molecular basis of mammalian circadian tim-
ing. Biochemistry 54: 134-49 [PMID:25303119]
Sousa EH et al. (2017) Drug discovery targeting heme-based sensors and their coupled activities. J
Inorg Biochem 167: 12-20 [PMID:27893989]
1F. Retinoic acid-related orphans
Nuclear hormone receptors→ 1F. Retinoic acid-related orphans
Overview: Retinoic acid receptor-related orphan receptors (ROR, nomenclature as agreed by the NC-IUPHAR Subcommittee on Nuclear Hormone Receptors [6]) have yet to be assigned a
deﬁnitive endogenous ligand, although RORα may be synthesized with a ‘captured’ agonist such as cholesterol [65, 66].
Nomenclature RAR-related orphan receptor-α RAR-related orphan receptor-β RAR-related orphan receptor-γ
Systematic nomenclature NR1F1 NR1F2 NR1F3
HGNC, UniProt RORA, P35398 RORB, Q92753 RORC, P51449
Endogenous agonists cholesterol [66, 114] – –
Selective agonists 7-hydroxycholesterol [14], cholesterol sulphate [14, 66] – –
Comments: tretinoin shows selectivity for RORβ within the ROR family [136]. RORα has been suggested to be a nuclear receptor responding to melatonin [154].
Further reading on 1F. Retinoic acid-related orphans
Benoit G et al. (2006) International Union of Pharmacology. LXVI. Orphan nuclear receptors.
Pharmacol. Rev. 58: 798-836 [PMID:17132856]
Cyr P et al. (2016) Recent progress on nuclear receptor RORgamma modulators. Bioorg Med Chem
Lett 26: 4387-93 [PMID:27542308]
Dahlman-Wright K et al. (2006) Overview of nomenclature of nuclear receptors. Pharmacol Rev 58:
685-704 [PMID:17132848]
Guillemot-Legris O et al. (2016) Oxysterols in Metabolic Syndrome: From Bystander Molecules to
Bioactive Lipids. Trends Mol Med 22: 594-614 [PMID:27286741]
Mutemberezi V et al. (2016) Oxysterols: From cholesterol metabolites to key mediators. Prog Lipid
Res 64: 152-169 [PMID:27687912]
Searchable database: http://www.guidetopharmacology.org/index.jsp 1F. Retinoic acid-related orphans S212
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1H. Liver X receptor-like receptors
Nuclear hormone receptors→ 1H. Liver X receptor-like receptors
Overview: Liver X and farnesoid X receptors (LXR and FXR, nomenclature as agreed by the NC-IUPHAR Subcommittee on Nuclear Hormone Receptors [105]) are members of a steroid
analogue-activated nuclear receptor subfamily, which form heterodimers with members of the retinoid X receptor family. Endogenous ligands for LXRs include hydroxycholesterols (OHC), while FXRs
appear to be activated by bile acids.
Nomenclature Farnesoid X receptor Farnesoid X receptor-β Liver X receptor-α Liver X receptor-β
Systematic
nomenclature
NR1H4 NR1H5 NR1H3 NR1H2
HGNC, UniProt NR1H4, Q96RI1 NR1H5P, – NR1H3, Q13133 NR1H2, P55055
Potency order chenodeoxycholic acid > lithocholic acid,
deoxycholic acid [92, 115]
– 20S-hydroxycholesterol,
22R-hydroxycholesterol,
24(S)-hydroxycholesterol >
25-hydroxycholesterol,
27-hydroxycholesterol [79]
20S-hydroxycholesterol,
22R-hydroxycholesterol,
24(S)-hydroxycholesterol >
25-hydroxycholesterol,
27-hydroxycholesterol [79]
Endogenous agonists – lanosterol [113] – Mouse – –
Selective agonists GW4064 [94], obeticholic acid [116],
fexaramine [36]
– – –
Selective antagonists guggulsterone (pIC50 5.7–6) [157] – – –
Comments: T0901317 [122] and GW3965 [27] are synthetic agonists acting at both LXRα and LXRβ with less than 10-fold selectivity.
Further reading on 1H. Liver X receptor-like receptors
Courtney R et al. (2016) LXR Regulation of Brain Cholesterol: FromDevelopment to Disease. Trends
Endocrinol Metab 27: 404-14 [PMID:27113081]
Gadaleta RM et al. (2017) Bile acids and colon cancer: Is FXR the solution of the conundrum? Mol
Aspects Med [PMID:28400119]
Merlen G et al. (2017) Bile acids and their receptors during liver regeneration: "Dangerous protec-
tors". Mol Aspects Med [PMID:28302491]
Moore DD et al. (2006) International Union of Pharmacology. LXII. The NR1H and NR1I receptors:
constitutive androstane receptor, pregnene X receptor, farnesoid X receptor alpha, farnesoid X
receptor beta, liver X receptor alpha, liver X receptor beta, and vitamin D receptor. Pharmacol
Rev 58: 742-59 [PMID:17132852]
Mouzat K et al. (2016) Liver X receptors: from cholesterol regulation to neuroprotection-a new
barrier against neurodegeneration in amyotrophic lateral sclerosis? Cell Mol Life Sci 73: 3801-8
[PMID:27510420]
Schulman IG. (2017) Liver X receptors link lipid metabolism and inﬂammation. FEBS Lett
[PMID:28555747]
Searchable database: http://www.guidetopharmacology.org/index.jsp 1H. Liver X receptor-like receptors S213
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1I. Vitamin D receptor-like receptors
Nuclear hormone receptors→ 1I. Vitamin D receptor-like receptors
Overview: Vitamin D (VDR), Pregnane X (PXR) and Constitutive Androstane (CAR) receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Nuclear Hormone Receptors
[105]) are members of the NR1I family of nuclear receptors, which form heterodimers with members of the retinoid X receptor family. PXR and CAR are activated by a range of exogenous compounds,
with no established endogenous physiological agonists, although high concentrations of bile acids and bile pigments activate PXR and CAR [105].
Nomenclature Vitamin D receptor Pregnane X receptor Constitutive androstane receptor
Systematic nomenclature NR1I1 NR1I2 NR1I3
HGNC, UniProt VDR, P11473 NR1I2, O75469 NR1I3, Q14994
Endogenous agonists 1,25-dihydroxyvitamin D3 [11, 39] 17β-estradiol [64] –
Selective agonists seocalcitol [28, 153], doxercalciferol hyperforin [106, 152], 5β-pregnane-3,20-dione
[64], lovastatin [81], rifampicin [15, 81]
TCPOBOP [144] – Mouse, CITCO [91]
Selective antagonists TEI-9647 (pIC50 8.2) [126] – Chicken,
ZK159222 (pIC50 7.5) [42, 60]
– –
Comments – – clotrimazole [107] and T0901317 [68] although
acting at other sites, function as antagonists of the
constitutive androstane receptor.
Further reading on 1I. Vitamin D receptor-like receptors
Benoit G et al. (2006) International Union of Pharmacology. LXVI. Orphan nuclear receptors.
Pharmacol. Rev. 58: 798-836 [PMID:17132856]
Long MD et al. (2015) Vitamin D receptor and RXR in the post-genomic era. J Cell Physiol. 230:
758-66 [PMID:25335912]
Moore DD et al. (2006) International Union of Pharmacology. LXII. The NR1H and NR1I receptors:
constitutive androstane receptor, pregnene X receptor, farnesoid X receptor alpha, farnesoid X
receptor beta, liver X receptor alpha, liver X receptor beta, and vitamin D receptor. Pharmacol.
Rev. 58: 742-59 [PMID:17132852]
2A. Hepatocyte nuclear factor-4 receptors
Nuclear hormone receptors→ 2A. Hepatocyte nuclear factor-4 receptors
Overview: The nomenclature of hepatocyte nuclear factor-4 receptors is agreed by the NC-IUPHAR Subcommittee on Nuclear Hormone Receptors [6]. While linoleic acid has been identiﬁed as
the endogenous ligand for HNF4α its function remains ambiguous [163]. HNF4γ has yet to be paired with an endogenous ligand.
Searchable database: http://www.guidetopharmacology.org/index.jsp 2A. Hepatocyte nuclear factor-4 receptors S214
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Nomenclature Hepatocyte nuclear factor-4-α Hepatocyte nuclear factor-4-γ
Systematic nomenclature NR2A1 NR2A2
HGNC, UniProt HNF4A, P41235 HNF4G, Q14541
Endogenous agonists linoleic acid [163] –
Selective antagonists BI6015 [71] –
Comments HNF4α has constitutive transactivation activity [163] and binds DNA as a homodimer [63]. –
Further reading on 2A. Hepatocyte nuclear factor-4 receptors
Benoit G et al. (2006) International Union of Pharmacology. LXVI. Orphan nuclear receptors.
Pharmacol. Rev. 58: 798-836 [PMID:17132856]
Germain P et al. (2006) Overview of nomenclature of nuclear receptors. Pharmacol. Rev. 58:
685-704 [PMID:17132848]
Garattini E et al. (2016) Lipid-sensors, enigmatic-orphan and orphan nuclear receptors as thera-
peutic targets in breast-cancer. Oncotarget 7: 42661-42682 [PMID:26894976]
Lu H. (2016) Crosstalk of HNF4alpha with extracellular and intracellular signaling pathways in
the regulation of hepatic metabolism of drugs and lipids. Acta Pharm Sin B 6: 393-408
[PMID:27709008]
Walesky CE et al. (2015) Role of hepatocyte nuclear factor 4alpha (HNF4alpha) in cell proliferation
and cancer. Gene Expr 16: 101-8[PMID:25700366]
2B. Retinoid X receptors
Nuclear hormone receptors→ 2B. Retinoid X receptors
Overview: Retinoid X receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Nuclear Hormone Receptors [45]) are NR2B family members activated by alitretinoin and
the RXR-selective agonists bexarotene and LG100268, sometimes referred to as rexinoids. UVI3003 [108] and HX 531 [37] have been described as a pan-RXR antagonists. These receptors form RXR-RAR
heterodimers and RXR-RXR homodimers [22, 96].
Nomenclature Retinoid X receptor-α Retinoid X receptor-β Retinoid X receptor-γ
Systematic nomenclature NR2B1 NR2B2 NR2B3
HGNC, UniProt RXRA, P19793 RXRB, P28702 RXRG, P48443
Sub/family-selective agonists bexarotene [16, 21, 141] bexarotene [16, 21, 141] bexarotene [16, 21, 141]
Selective agonists CD3254 [48] – –
Searchable database: http://www.guidetopharmacology.org/index.jsp 2B. Retinoid X receptors S215
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Further reading on 2B. Retinoid X receptors
Germain P et al. (2006) International Union of Pharmacology. LXIII. Retinoid X receptors. Phar-
macol. Rev. 58: 760-72 [PMID:17132853]
Long MD et al. (2015) Vitamin D receptor and RXR in the post-genomic era. J Cell Physiol 230:
758-66 [PMID:25335912]
Menendez-Gutierrez MP et al. (2017) The multi-faceted role of retinoid X receptor in bone remod-
eling. Cell Mol Life Sci 74: 2135-2149 [PMID:28105491]
2C. Testicular receptors
Nuclear hormone receptors→ 2C. Testicular receptors
Overview: Testicular receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Nuclear Hormone Receptors [6]) have yet to be ofﬁcially paired with an endogenous ligand,
although testicular receptor 4 has been reported to respond to retinoids.
Nomenclature Testicular receptor 2 Testicular receptor 4
Systematic nomenclature NR2C1 NR2C2
HGNC, UniProt NR2C1, P13056 NR2C2, P49116
Endogenous agonists – retinol [169], tretinoin [169]
Comments Forms a heterodimer with TR4; gene disruption appears without effect on testicular development or function [132]. Forms a heterodimer with TR2.
Further reading on 2C. Testicular receptors
Benoit G et al. (2006) International Union of Pharmacology. LXVI. Orphan nuclear receptors.
Pharmacol. Rev. 58: 798-836 [PMID:17132856]
Dahlman-Wright K et al. (2006) Overview of nomenclature of nuclear receptors. Pharmacol Rev 58:
685-704 [PMID:17132848]
Safe S et al. (2014) Minireview: role of orphan nuclear receptors in cancer and potential as drug
targets. Mol Endocrinol 28: 157-72 [PMID:24295738]
Wu D et al. (2016) The emerging roles of orphan nuclear receptors in prostate cancer. Biochim.
Biophys. Acta 1866: 23-36 [PMID:27264242]
2E. Tailless-like receptors
Nuclear hormone receptors→ 2E. Tailless-like receptors
Overview: Tailless-like receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Nuclear Hormone Receptors [6]) have yet to be ofﬁcially paired with an endogenous ligand.
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Nomenclature TLX PNR
Systematic nomenclature NR2E1 NR2E3
HGNC, UniProt NR2E1, Q9Y466 NR2E3, Q9Y5X4
Comments Gene disruption is associated with abnormal brain development [75, 104]. –
Further reading on 2E. Tailless-like receptors
Benod C et al. (2016) TLX: An elusive receptor. J. Steroid Biochem. Mol. Biol. 157: 41-7
[PMID:26554934]
Benoit G et al. (2006) International Union of Pharmacology. LXVI. Orphan nuclear receptors.
Pharmacol. Rev. 58: 798-836 [PMID:17132856]
Germain P et al. (2006) Overview of nomenclature of nuclear receptors. Pharmacol. Rev. 58: 685-
704 [PMID:17132848]
2F. COUP-TF-like receptors
Nuclear hormone receptors→ 2F. COUP-TF-like receptors
Overview: COUP-TF-like receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Nuclear Hormone Receptors [6]) have yet to be ofﬁcially paired with an endogenous
ligand.
Nomenclature COUP-TF1 COUP-TF2 V-erbA-related gene
Systematic nomenclature NR2F1 NR2F2 NR2F6
HGNC, UniProt NR2F1, P10589 NR2F2, P24468 NR2F6, P10588
Comments Gene disruption is perinatally lethal [120]. Gene disruption is embryonically lethal [117]. Gene disruption impairs CNS development [151].
Further reading on 2F. COUP-TF-like receptors
Benoit G et al. (2006) International Union of Pharmacology. LXVI. Orphan nuclear receptors.
Pharmacol. Rev. 58: 798-836 [PMID:17132856]
Germain P et al. (2006) Overview of nomenclature of nuclear receptors. Pharmacol. Rev. 58: 685-
704 [PMID:17132848]
Wu D et al. (2016) The emerging roles of orphan nuclear receptors in prostate cancer. Biochim.
Biophys. Acta 1866: 23-36 [PMID:27264242]
Wu SP et al. (2016) Choose your destiny: Make a cell fate decision with COUP-TFII. J Steroid Biochem
Mol Biol 157: 7-12 [PMID:26658017]
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3B. Estrogen-related receptors
Nuclear hormone receptors→ 3B. Estrogen-related receptors
Overview: Estrogen-related receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Nuclear Hormone Receptors [6]) have yet to be ofﬁcially paired with an endogenous
ligand.
Nomenclature Estrogen-related receptor-α Estrogen-related receptor-β Estrogen-related receptor-γ
Systematic nomenclature NR3B1 NR3B2 NR3B3
HGNC, UniProt ESRRA, P11474 ESRRB, O95718 ESRRG, P62508
Comments Activated by some dietary ﬂavonoids [138]; activated by the synthetic
agonist GSK4716 [181] and blocked by XCT790 [156].
May be activated by DY131 [162]. May be activated by DY131 [162].
Further reading on 3B. Estrogen-related receptors
Benoit G et al. (2006) International Union of Pharmacology. LXVI. Orphan nuclear receptors.
Pharmacol. Rev. 58: 798-836 [PMID:17132856]
Divekar SD et al. (2016) Estrogen-related receptor β (ERRβ) - renaissance receptor or receptor re-
naissance? Nucl Recept Signal 14: e002 [PMID:27507929]
Germain P et al. (2006) Overview of nomenclature of nuclear receptors. Pharmacol. Rev. 58: 685-
704 [PMID:17132848]
Tam IS et al. (2016) There and back again: The journey of the estrogen-related receptors in the
cancer realm. J Steroid Biochem Mol Biol 157: 13-9[PMID:26151739]
Wu D et al. (2016) The emerging roles of orphan nuclear receptors in prostate cancer. Biochim.
Biophys. Acta 1866: 23-36 [PMID:27264242]
4A. Nerve growth factor IB-like receptors
Nuclear hormone receptors→ 4A. Nerve growth factor IB-like receptors
Overview: Nerve growth factor IB-like receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Nuclear Hormone Receptors [6]) have yet to be ofﬁcially paired with an
endogenous ligand.
Nomenclature Nerve Growth factor IB
Nuclear receptor related 1 Neuron-derived orphan receptor 1
Systematic nomenclature NR4A1 NR4A2 NR4A3
HGNC, UniProt NR4A1, P22736 NR4A2, P43354 NR4A3, Q92570
Comments An endogenous agonist, cytosporone B, has been described [164], although structural
analysis and molecular modelling has not identiﬁed a ligand binding site [4, 40, 150].
– –
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Further reading on 4A. Nerve growth factor IB-like receptors
Benoit G et al. (2006) International Union of Pharmacology. LXVI. Orphan nuclear receptors.
Pharmacol. Rev. 58: 798-836 [PMID:17132856]
Germain P et al. (2006) Overview of nomenclature of nuclear receptors. Pharmacol. Rev. 58: 685-
704 [PMID:17132848]
Ranhotra HS. (2015) The NR4A orphan nuclear receptors: mediators in metabolism and diseases. J
Recept Signal Transduct Res 35: 184-8 [PMID:25089663]
Rodriguez-Calvo R et al. (2017) The NR4A subfamily of nuclear receptors: potential new therapeu-
tic targets for the treatment of inﬂammatory diseases. Expert Opin Ther Targets 21: 291-304
[PMID:28055275]
Safe S et al. (2016) Nuclear receptor 4A (NR4A) family - orphans no more. J Steroid Biochem Mol Biol
157: 48-60 [PMID:25917081]
5A. Fushi tarazu F1-like receptors
Nuclear hormone receptors→ 5A. Fushi tarazu F1-like receptors
Overview: Fushi tarazu F1-like receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Nuclear Hormone Receptors [6]) have yet to be ofﬁcially paired with an endogenous
ligand.
Nomenclature Steroidogenic factor 1 Liver receptor homolog-1
Systematic nomenclature NR5A1 NR5A2
HGNC, UniProt NR5A1, Q13285 NR5A2, O00482
Comments Reported to be inhibited by AC45594 [32] and SID7969543 [90]. –
Further reading on 5A. Fushi tarazu F1-like receptors
Benoit G et al. (2006) International Union of Pharmacology. LXVI. Orphan nuclear receptors.
Pharmacol. Rev. 58: 798-836 [PMID:17132856]
Garattini E et al. (2016) Lipid-sensors, enigmatic-orphan and orphan nuclear receptors as thera-
peutic targets in breast-cancer. Oncotarget. 7: 42661-42682 [PMID:26894976]
Germain P et al. (2006) Overview of nomenclature of nuclear receptors. Pharmacol. Rev. 58:
685-704 [PMID:17132848]
Zhi X et al. (2016) Structures and regulation of non-X orphan nuclear receptors: A retinoid hy-
pothesis. J Steroid Biochem Mol Biol. 157: 27-40 [PMID:26159912]
Zimmer V et al. (2015) Nuclear receptor variants in liver disease. Dig Dis. 33: 415-9
[PMID:26045277]
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6A. Germ cell nuclear factor receptors
Nuclear hormone receptors→ 6A. Germ cell nuclear factor receptors
Overview: Germ cell nuclear factor receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Nuclear Hormone Receptors [6]) have yet to be ofﬁcially paired with an
endogenous ligand.
Nomenclature Germ cell nuclear factor
Systematic nomenclature NR6A1
HGNC, UniProt NR6A1, Q15406
Further reading on 6A. Germ cell nuclear factor receptors
Benoit G et al. (2006) International Union of Pharmacology. LXVI. Orphan nuclear receptors.
Pharmacol. Rev. 58: 798-836 [PMID:17132856]
Garattini E et al. (2006) Lipid-sensors, enigmatic-orphan and orphan nuclear receptors as thera-
peutic targets in breast-cancer. Oncotarget. 7: 42661-42682 [PMID:26894976]
Germain P et al. (2006) Overview of nomenclature of nuclear receptors. Pharmacol. Rev. 58:
685-704 [PMID:17132848]
Safe S et al. ((2014) Minireview: role of orphan nuclear receptors in cancer and potential as drug
targets. Mol Endocrinol. 28: 157-72 [PMID:24295738]
Zhi X et al. (2016) Structures and regulation of non-X orphan nuclear receptors: A retinoid hy-
pothesis. J Steroid Biochem Mol Biol. 157: 27-40 [PMID:26159912]
0B. DAX-like receptors
Nuclear hormone receptors→ 0B. DAX-like receptors
Overview: Dax-like receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Nuclear Hormone Receptors [6]) have yet to be ofﬁcially paired with an endogenous ligand.
Nomenclature DAX1 SHP
Systematic nomenclature NR0B1 NR0B2
HGNC, UniProt NR0B1, P51843 NR0B2, Q15466
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Further reading on 0B. DAX-like receptors
Benoit G et al. (2006) International Union of Pharmacology. LXVI. Orphan nuclear receptors.
Pharmacol. Rev. 58: 798-836 [PMID:17132856]
Garattini E et al. (2016) Lipid-sensors, enigmatic-orphan and orphan nuclear receptors as thera-
peutic targets in breast-cancer. Oncotarget 7: 42661-42682 [PMID:26894976]
Germain P et al. (2006) Overview of nomenclature of nuclear receptors. Pharmacol. Rev. 58:
685-704 [PMID:17132848]
Safe S et al. (2014) Minireview: role of orphan nuclear receptors in cancer and potential as drug
targets. Mol Endocrinol 28: 157-72 [PMID:24295738]
Wu D et al. (2016) The emerging roles of orphan nuclear receptors in prostate cancer. Biochim.
Biophys. Acta 1866: 23-36 [PMID:27264242]
Steroid hormone receptors
Nuclear hormone receptors→ Steroid hormone receptors
Overview: Steroid hormone receptors (nomenclature as
agreed by the NC-IUPHAR Subcommittee on Nuclear
Hormone Receptors [30, 87]) are nuclear hormone recep-
tors of the NR3 class, with endogenous agonists that may be
divided into 3-hydroxysteroids (estrone and 17β-estradiol) and
3-ketosteroids (dihydrotestosterone [DHT], aldosterone, cortisol,
corticosterone, progesterone and testosterone). These recep-
tors exist as dimers coupled with chaperone molecules (such as
hsp90β (HSP90AB1, P08238) and immunophilin FKBP52:FKBP4,
Q02790), which are shed on binding the steroid hormone. Al-
though rapid signalling phenomena are observed [83, 119], the
principal signalling cascade appears to involve binding of the
activated receptors to nuclear hormone response elements of
the genome, with a 15-nucleotide consensus sequence AGAA-
CAnnnTGTTCT (i.e. an inverted palindrome) as homo- or het-
erodimers. They also affect transcription by protein-protein
interactions with other transcription factors, such as activator
protein 1 (AP-1) and nuclear factor κB (NF-κB). Splice vari-
ants of each of these receptors can form functional or non-
functional monomers that can dimerize to form functional or
non-functional receptors. For example, alternative splicing of PR
mRNA produces A and B monomers that combine to produce
functional AA, AB and BB receptors with distinct characteristics
[145].
A 7TM receptor responsive to estrogen (GPER1, Q99527, also
known as GPR30, see [118]) has been described. Human ortho-
logues of 7TM ’membrane progestin receptors’ (PAQR7, PAQR8
and PAQR5), initially discovered in ﬁsh [170, 171], appear to lo-
calize to intracellular membranes and respond to ’non-genomic’
progesterone analogues independently of G proteins [134].
3A. Estrogen receptors
Nuclear hormone receptors→ Steroid hormone receptors→ 3A. Estrogen receptors
Overview: Estrogen receptor (ER) activity regulates diverse physiological processes via transcriptional modulation of target genes. The selection of target genes and the magnitude of the response, be it
induction or repression, are determined by many factors, including the effect of the hormone ligand and DNA binding on ER structural conformation, and the local cellular regulatory environment. The
cellular environment deﬁnes the speciﬁc complement of DNA enhancer and promoter elements present and the availability of coregulators to form functional transcription complexes. Together, these
determinants control the resulting biological response.
Nomenclature Estrogen receptor-α Estrogen receptor-β
Systematic nomenclature NR3A1 NR3A2
HGNC, UniProt ESR1, P03372 ESR2, Q92731
Endogenous agonists estriol [74], estrone [74] –
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(continued)
Nomenclature Estrogen receptor-α Estrogen receptor-β
Selective agonists propylpyrazoletriol [73, 135], ethinylestradiol [62] WAY200070 [93], diarylpropionitrile [100, 135], prinaberel [29, 93]
Sub/family-selective antagonists bazedoxifene (pIC50 7.6) [103] bazedoxifene (pIC50 7.1) [103]
Selective antagonists clomiphene (pKi 8.9) [3], methyl-piperidino-pyrazole (pKi 8.6) [139] R,R-THC (pKi 8.4) [99, 140], PHTPP (pKi 6.9) [168]
Comments: R,R-THC exhibits partial agonist activity at ERα [99, 140]. Estrogen receptors may be blocked non-selectively by tamoxifen and raloxifene and labelled by [3H]17β-estradiol and [3H]tamoxifen.
Many agents thought initially to be antagonists at estrogen receptors appear to have tissue-speciﬁc efﬁcacy (e.g. Tamoxifen is an antagonist at estrogen receptors in the breast, but is an agonist at estrogen
receptors in the uterus), hence the descriptor SERM (selective estrogen receptor modulator) or SnuRM (selective nuclear receptor modulator). Y134 has been suggested to be an ERα-selective estrogen
receptor modulator [111].
Further reading on 3A. Estrogen receptors
Dahlman-Wright K et al. (2016) Estrogen Receptor Ligands: A Review (2013-2015). Sci Pharm 84:
409-427 [PMID:28117309]
Gonzalez-Sanchez E et al. (2015) Nuclear receptors in acute and chronic cholestasis. Dig Dis 33:
357-66 [PMID:26045270]
Gustafsson (2006) International Union of Pharmacology. LXIV. Estrogen receptors. Pharmacol Rev
58: 773-81 [PMID:17132854]
Hewitt SC et al. (2016) What’s new in estrogen receptor action in the female reproductive tract. J.
Mol. Endocrinol. 56: R55-71 [PMID:26826253]
Jameera Begam A et al. (2017) Estrogen receptor agonists/antagonists in breast cancer therapy: A
critical review. Bioorg Chem 71: 257-274 [PMID:28274582]
Warner M et al. (2017) Estrogen Receptor β as a Pharmaceutical Target. Trends Pharmacol. Sci. 38:
92-99 [PMID:27979317]
3C. 3-Ketosteroid receptors
Nuclear hormone receptors→ Steroid hormone receptors→ 3C. 3-Ketosteroid receptors
Nomenclature Androgen receptor Glucocorticoid receptor
Systematic nomenclature NR3C4 NR3C1
HGNC, UniProt AR, P10275 NR3C1, P04150
Rank order of potency dihydrotestosterone [142]> testosterone cortisol, corticosterone aldosterone, deoxycortisone [125]
Selective agonists testosterone propionate [95], mibolerone [49], ﬂuoxymesterone [61],
methyltrienolone [148], dromostanolone propionate
ﬂuticasone propionate [10], beclometasone [3], methylprednisolone [3],
ﬂuocinonide [3], betamethasone [3], budesonide [102]
Selective antagonists bicalutamide (pKi 7.7) [70], PF0998425 (pIC50 7.1–7.5) [85], enzalutamide
(pIC50 7.4) [143], nilutamide (pIC50 7.1–7.1) [133], hydroxyﬂutamide (pEC50
6.6) [148], galeterone (pIC50 6.4) [56], ﬂutamide (pKi 5.4) [147]
onapristone (pIC50 7.6) [165], ZK112993
Labelled ligands [3H]dihydrotestosterone (Selective Agonist), [3H]methyltrienolone (Selective
Agonist), [3H]mibolerone (Agonist)
[3H]dexamethasone (Agonist)
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Nomenclature Mineralocorticoid receptor Progesterone receptor
Systematic nomenclature NR3C2 NR3C3
HGNC, UniProt NR3C2, P08235 PGR, P06401
Rank order of potency corticosterone, cortisol, aldosterone [58, 125], progesterone [125] progesterone [38]
Selective agonists – medroxyprogesterone (Afﬁnity at human PR-A) [166], ORG2058, levonorgestrel [9, 128]
Selective antagonists ﬁnerenone (pIC50 7.7) [20], eplerenone (pKi 6.9) [5], onapristone
(pIC50 6.3) [165], RU28318, ZK112993
ulipristal acetate (pIC50 9.7) [123], mifepristone (Mixed) (pKi 9) [167], onapristone (pKi
7.7) [54], ZK112993
Labelled ligands [3H]aldosterone (Selective Agonist) [44, 137] – Rat [3H]ORG2058 (Selective Agonist)
Comments: [3H]dexamethasone also binds to MR in vitro. PR antagonists have been suggested to subdivide into Type I (e.g. onapristone) and Type II (e.g. ZK112993) groups. These groups appear to
promote binding of PR to DNA with different efﬁcacies and evoke distinct conformational changes in the receptor, leading to a transcription-neutral complex [43, 82]. Mutations in AR underlie testicular
feminization and androgen insensitivity syndromes, spinal and bulbar muscular atrophy (Kennedy’s disease).
Further reading on 3C. 3-Ketosteroid receptors
Baker ME et al. (2017) 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Evolution of
the mineralocorticoid receptor: sequence, structure and function. J Endocrinol 234: T1-T16
[PMID:28468932]
Carroll JS et al. (2017) Deciphering the divergent roles of progestogens in breast cancer. Nat Rev
Cancer 17: 54-64 [PMID:27885264]
Cohen DM et al. (2017) Nuclear Receptor Function through Genomics: Lessons from the Gluco-
corticoid Receptor. Trends Endocrinol Metab 28: 531-540 [PMID:28495406]
de Kloet ER et al. (2017) Brain mineralocorticoid receptor function in control of salt balance and
stress-adaptation. Physiol. Behav. [PMID:28089704]
Garg D, et al. (2017) Progesterone-Mediated Non-Classical Signaling. Trends Endocrinol Metab
[PMID:28651856]
Lu NZ et al. (2006) International Union of Pharmacology. LXV. The pharmacology and classiﬁca-
tion of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and
androgen receptors. Pharmacol Rev 58: 782-97 [PMID:17132855]
Lucas-Herald AK et al. (2017) Genomic and non-genomic effects of androgens in the cardiovascular
system: clinical implications. Clin Sci (Lond) 131: 1405-1418 [PMID:28645930]
Wadosky KM et al. (2017) Androgen receptor splice variants and prostate cancer: From bench to
bedside. Oncotarget 8: 18550-18576 [PMID:28077788]
Weikum ER et al. (2017) Glucocorticoid receptor control of transcription: precision and plasticity
via allostery. Nat Rev Mol Cell Biol 18: 159-174 [PMID:28053348]
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